An improved method for constructing tissue microarrays from prostate needle biopsy specimens

Journal of Clinical Pathology

Volumn 62, Issue 8, 2009, Pages 694-698

  McCarthy, F ^a   Fletcher, A ^a   Dennis, N ^a   Cummings, C ^a   O'Donnell, H ^b   Clark, J ^a   Flohr, P ^a   Vergis, R ^b   Jhavar, S ^b   Parker, C ^b   Cooper, C S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FISH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TISSUE MICROARRAY;

BIOPSY, NEEDLE; FIXATIVES; FORMALDEHYDE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; PARAFFIN EMBEDDING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 68149124535     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.065201     Document Type: Article

References (16)

1. Khor LY, DeSilvio M, Al Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer 2005;104:962-967 (Pubitemid 41170223)
2. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res 2007;13:3585-3590 (Pubitemid 46955119)
3. Singh SS, Mehedint DC, Ford OH III, et al. Feasibility of constructing tissue microarrays from diagnostic prostate biopsies. Prostate 2007;67:1011-1018
4. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-847 (Pubitemid 28331029)
5. Jhavar S, Corbishley CM, Dearnaley D, et al. Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer 2005;93:478-482 (Pubitemid 43080024)
6. Vergis R, Corbishley C, Norman A, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer predict the outcome of radical treatment. Lancet Oncol 2008;9:342-351
7. Jhavar S, Bartlett J, Kovacs G, et al. Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 2009;12:143-147
8. Datta MW, Kahler A, Macias V, et al. A simple inexpensive method for the production of tissue microarrays from needle biopsy specimens: examples with prostate cancer. Appl Immunohistochem Mol Morphol 2005;13:96-103. (Pubitemid 40283810)
9. Attard G, Reid A, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571
10. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008;27:1993-2003.
11. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648 (Pubitemid 41528150)
12. Clark J, Attard G, Jhavar S, et al. Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene 2008;27:1993-2003.
13. Wang J, Cai Y, Ren C, et al. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351 (Pubitemid 44449142)
14. Jhavar S, Brewer D, Edwards S, et al. Integration of ERG gene mapping and gene expression profiling identifies distinct categories of human prostate cancer. BJU Int 2009;103:1256-1269
15. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858-887 (Pubitemid 40461690)
16. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004;10:3943-3953 (Pubitemid 38812467)